These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 6885106)

  • 21. Synergistic activation of macrophages via CD40 and TLR9 results in T cell independent antitumor effects.
    Buhtoiarov IN; Lum HD; Berke G; Sondel PM; Rakhmilevich AL
    J Immunol; 2006 Jan; 176(1):309-18. PubMed ID: 16365423
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Induction of macrophage suppressor activity by fibrosarcoma-derived transforming growth factor-beta 1: contrasting effects on resting and activated macrophages.
    Alleva DG; Walker TM; Elgert KD
    J Leukoc Biol; 1995 Jun; 57(6):919-28. PubMed ID: 7790775
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Macrophage priming and activation during fibrosarcoma growth: expression of c-myb, c-myc, c-fos, and c-fms.
    Alleva DG; Askew D; Burger CJ; Elgert KD
    Immunol Invest; 1994 Nov; 23(6-7):457-72. PubMed ID: 7851963
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Depression of protective mechanisms against ectromelia virus infection in tumor-bearing mice and its prevention by PSK].
    Taniguchi M; Tsuru S; Kitani H; Zinnaka Y; Nomoto K
    Gan To Kagaku Ryoho; 1984 Dec; 11(12 Pt 2):2760-5. PubMed ID: 6095765
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vivo macrophage-mediated tumor cytotoxicity in the mouse.
    Cameron DJ
    Immunol Lett; 1982 Jun; 4(6):321-5. PubMed ID: 6811424
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increased prostaglandin synthesis by macrophages from tumor-bearing mice.
    Pelus LM; Bockman RS
    J Immunol; 1979 Nov; 123(5):2118-25. PubMed ID: 489975
    [No Abstract]   [Full Text] [Related]  

  • 27. [Induction of activated macrophages by intraperitoneal injection of mitomycin C in mice and rats].
    Ogura T
    Gan To Kagaku Ryoho; 1986 Mar; 13(3 Pt 2):689-96. PubMed ID: 3083782
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Direct activation of murine peritoneal macrophages for nitric oxide production and tumor cell killing by interferon-gamma.
    Dileepan KN; Page JC; Li Y; Stechschulte DJ
    J Interferon Cytokine Res; 1995 May; 15(5):387-94. PubMed ID: 7648440
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunotherapy of murine sarcoma by adoptive transfer of resident peritoneal macrophages proliferating in culture.
    Bartholeyns J; Lombard Y; Poindron P
    Anticancer Res; 1988; 8(1):145-51. PubMed ID: 3358630
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vitro cytotoxicity of mouse macrophages activated by coculture with syngeneic sarcoma cells.
    Olstad R; Kaplan G; Seljelid R
    Scand J Immunol; 1982 Nov; 16(5):421-30. PubMed ID: 6983715
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Amplification by macrophages of prostaglandin-mediated immunosuppression in mice bearing syngeneic tumors.
    Plescia OJ; Pontieri GM; Brown J; Racis S; Ippoliti F; Bellelli L; Sezzi ML; Lipari M
    Prostaglandins Leukot Med; 1984 Nov; 16(2):205-23. PubMed ID: 6597451
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunologic significance of nonspecific suppressor cells in spleens of tumor-bearing mice.
    Hanna N; Kripke ML
    Cell Immunol; 1979 Mar; 43(2):293-303. PubMed ID: 314343
    [No Abstract]   [Full Text] [Related]  

  • 33. Level of activation determines whether inflammatory peritoneal and intratumoral macrophages will promote or suppress in vitro development of cytolytic T lymphocyte activity.
    Gillespie GY; Russell SW
    J Reticuloendothel Soc; 1980 May; 27(5):535-45. PubMed ID: 7373614
    [No Abstract]   [Full Text] [Related]  

  • 34. Immunoregulating activity of tumor-associated macrophages.
    Dougherty GJ; McBride WH
    Cancer Immunol Immunother; 1986; 23(1):67-72. PubMed ID: 3464353
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Macrophage activation for tumor cytotoxicity: control of cytotoxic activity by the time interval effector and target cells are exposed to lymphokines.
    Nakamura RM; Meltzer MS
    Cell Immunol; 1981 Nov; 65(1):52-65. PubMed ID: 7317951
    [No Abstract]   [Full Text] [Related]  

  • 36. IFN-gamma differentially modulates the susceptibility of L1210 and P815 tumor targets for macrophage-mediated cytotoxicity. Role of macrophage-target interaction coupled to nitric oxide generation, but independent of tumor necrosis factor production.
    Leu RW; Leu NR; Shannon BJ; Fast DJ
    J Immunol; 1991 Sep; 147(6):1816-22. PubMed ID: 1909732
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Defective macrophage function in neonates and its impact on unresponsiveness of neonates to polysaccharide antigens.
    Chelvarajan RL; Collins SM; Doubinskaia IE; Goes S; Van Willigen J; Flanagan D; De Villiers WJ; Bryson JS; Bondada S
    J Leukoc Biol; 2004 Jun; 75(6):982-94. PubMed ID: 14982942
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biphasic depression of macrophage function after tumor transplantation.
    Normann SJ; Schardt M; Sorkin E
    Int J Cancer; 1981 Aug; 28(2):185-90. PubMed ID: 7033145
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of mitogen and immune blastogenesis by two distinct populations of supressor cells present in the spleens of fibrosarcoma-bearing mice: adoptive transfer of suppression.
    Farrar WL; Elgert KD
    Int J Cancer; 1978 Aug; 22(2):142-51. PubMed ID: 308934
    [No Abstract]   [Full Text] [Related]  

  • 40. Simple estimation of macrophage activity in tumour-bearing animals treated with Corynebacterium parvum.
    Wilson RG
    Br J Exp Pathol; 1981 Aug; 62(4):347-9. PubMed ID: 7295527
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.